93 related articles for article (PubMed ID: 20530806)
1. Impact of haemoglobin and erythropoietin dose changes on mortality: a secondary analysis of results from a randomized anaemia management trial.
Lau JH; Gangji AS; Rabbat CG; Brimble KS
Nephrol Dial Transplant; 2010 Dec; 25(12):4002-9. PubMed ID: 20530806
[TBL] [Abstract][Full Text] [Related]
2. Mortality in incident haemodialysis patients: time-dependent haemoglobin levels and erythropoiesis-stimulating agent dose are independent predictive factors in the ANSWER study.
Fort J; Cuevas X; García F; Pérez-García R; Lladós F; Lozano J; Martín-Malo A;
Nephrol Dial Transplant; 2010 Aug; 25(8):2702-10. PubMed ID: 20176608
[TBL] [Abstract][Full Text] [Related]
3. It's time to compare anemia management strategies in hemodialysis.
Coyne DW
Clin J Am Soc Nephrol; 2010 Apr; 5(4):740-2. PubMed ID: 20299363
[TBL] [Abstract][Full Text] [Related]
4. Sex-specific association of time-varying haemoglobin values with mortality in incident dialysis patients.
Sturm G; Lamina C; Zitt E; Lhotta K; Lins F; Freistätter O; Neyer U; Kronenberg F
Nephrol Dial Transplant; 2010 Aug; 25(8):2715-22. PubMed ID: 20190241
[TBL] [Abstract][Full Text] [Related]
5. Intravenous iron in chronic kidney disease: haemoglobin change shortly after treatment of patients neither on dialysis nor on erythropoietin.
Tagboto S; Cropper L; Mostafa S; Turner J; Bailey G; Pugh-Clarke K
J Ren Care; 2008 Sep; 34(3):112-5. PubMed ID: 18786076
[TBL] [Abstract][Full Text] [Related]
6. Haemoglobin at time of referral prior to dialysis predicts survival: an association of haemoglobin with long-term outcomes.
Levin A; Djurdjev O; Duncan J; Rosenbaum D; Werb R
Nephrol Dial Transplant; 2006 Feb; 21(2):370-7. PubMed ID: 16249203
[TBL] [Abstract][Full Text] [Related]
7. Initiation of anaemia management in patients with chronic kidney disease not on dialysis in the Veterans Health Administration.
Lawler EV; Gagnon DR; Fink J; Seliger S; Fonda J; Do TP; Gaziano JM; Bradbury BD
Nephrol Dial Transplant; 2010 Jul; 25(7):2237-44. PubMed ID: 20083469
[TBL] [Abstract][Full Text] [Related]
8. Cardiorenal anemia syndrome: do erythropoietin and iron therapy have a place in the treatment of heart failure?
Pagourelias ED; Koumaras C; Kakafika AI; Tziomalos K; Zorou PG; Athyros VG; Karagiannis A
Angiology; 2009; 60(1):74-81. PubMed ID: 18413330
[TBL] [Abstract][Full Text] [Related]
9. Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients.
Mircescu G; Gârneata L; Capusa C; Ursea N
Nephrol Dial Transplant; 2006 Jan; 21(1):120-4. PubMed ID: 16144853
[TBL] [Abstract][Full Text] [Related]
10. Use of 12x/month haemoglobin monitoring with a computer algorithm reduces haemoglobin variability.
Ho WR; Germain MJ; Garb J; Picard S; Mackie MK; Bartlett C; Will EJ
Nephrol Dial Transplant; 2010 Aug; 25(8):2710-4. PubMed ID: 20176613
[TBL] [Abstract][Full Text] [Related]
11. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
12. Hemoglobin level variability in renal transplant patients treated with erythropoiesis stimulating agents.
Fernández Fresnedo G; de Francisco AL; Ruiz JC; Gómez Alamillo C; Arias M
Transplant Proc; 2008 Nov; 40(9):2919-21. PubMed ID: 19010147
[TBL] [Abstract][Full Text] [Related]
13. Effect of variability in anemia management on hemoglobin outcomes in ESRD.
Lacson E; Ofsthun N; Lazarus JM
Am J Kidney Dis; 2003 Jan; 41(1):111-24. PubMed ID: 12500228
[TBL] [Abstract][Full Text] [Related]
14. Pentoxifylline improves haemoglobin and interleukin-6 levels in chronic kidney disease.
Ferrari P; Mallon D; Trinder D; Olynyk JK
Nephrology (Carlton); 2010 Apr; 15(3):344-9. PubMed ID: 20470305
[TBL] [Abstract][Full Text] [Related]
15. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
Provenzano R; Besarab A; Macdougall IC; Ellison DH; Maxwell AP; Sulowicz W; Klinger M; Rutkowski B; Correa-Rotter R; Dougherty FC;
Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
[TBL] [Abstract][Full Text] [Related]
16. Triumph and tragedy: anemia management in chronic kidney disease.
Novak JE; Szczech LA
Curr Opin Nephrol Hypertens; 2008 Nov; 17(6):580-8. PubMed ID: 18941350
[TBL] [Abstract][Full Text] [Related]
17. Hemoglobin control, ESA resistance, and regular low-dose IV iron therapy: a review of the evidence.
Singh A
Semin Dial; 2009; 22(1):64-9. PubMed ID: 19175537
[TBL] [Abstract][Full Text] [Related]
18. [Regarding the optimal hemoglobin target range in renal anemia].
Maurin N
Med Klin (Munich); 2008 Sep; 103(9):633-7. PubMed ID: 18813886
[TBL] [Abstract][Full Text] [Related]
19. Randomized evaluation of efficacy and safety of ferric carboxymaltose in patients with iron deficiency anaemia and impaired renal function (REPAIR-IDA): rationale and study design.
Szczech LA; Bregman DB; Harrington RA; Morris D; Butcher A; Koch TA; Goodnough LT; Wolf M; Onken JE
Nephrol Dial Transplant; 2010 Jul; 25(7):2368-75. PubMed ID: 20466657
[TBL] [Abstract][Full Text] [Related]
20. Would artificial neural networks implemented in clinical wards help nephrologists in predicting epoetin responsiveness?
Gabutti L; Lötscher N; Bianda J; Marone C; Mombelli G; Burnier M
BMC Nephrol; 2006 Sep; 7():13. PubMed ID: 16981983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
